Praxis Precision Medicines (PRAX) EBIT Margin (2023 - 2024)
Praxis Precision Medicines' (PRAX) quarterly EBIT Margin came in at 856.97% in Q4 2024, up 454225.0% year-on-year from N/an in Q1 2024, and up 95.45% quarter-over-quarter from 18819.54% in Q3 2024.
Praxis Precision Medicines (PRAX) EBIT Margin (2023 - 2024) Analysis & Trends
Praxis Precision Medicines' EBIT Margin history runs 2 years deep, the most recent figure standing at 856.97% for Q4 2024.
- On a quarterly basis, EBIT Margin rose 454225.0% year-over-year to 856.97% in Q4 2024; TTM through Sep 2025 was 3927.51%, a 629149.0% increase from a year earlier, with the FY2024 full-year figure at 2340.29%, up 282412.0% from the prior year.
- EBIT Margin improved to 856.97% in Q4 2024 per PRAX's latest filing, from 18819.54% in the prior quarter.
- Across five years, EBIT Margin topped out at 856.97% in Q4 2024 and bottomed at 18819.54% in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Praxis Precision Medicines | 8.98 Bn | 8.20 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -856.97% |
| Sep 30, 2024 | -18,819.54% |
| Jun 30, 2024 | -10,500.84% |
| Mar 31, 2024 | -9,718.33% |
| Dec 31, 2023 | -5,399.22% |
| Sep 30, 2023 | -5,452.14% |
| Jun 30, 2023 | -4,476.31% |
| Mar 31, 2023 | -5,577.01% |